Cohort profile: Design and first results of the Dutch IBD Biobank: A prospective, nationwide biobank of patients with inflammatory bowel disease
Spekhorst, Lieke M; Imhann, Floris; Festen, Eleonora Am; Van Bodegraven, Ad A.; Boer, Nanne Kh de; Bouma, Gerd; Fidder, Herma H; D'Haens, Geert R.; Hoentjen, Frank; Hommes, Daan W; de Jong, Dirk J; Löwenberg, Mark; Maljaars, Pw Jeroen; Van der Meulen-de Jong, Andrea E; Oldenburg, Bas; Pierik, Marieke J.; Ponsioen, Cyriel Y; Stokkers, Pieter C.; Verspaget, Hein W; Visschedijk, Marijn C; van der Woude, C Janneke; Dijkstra, Gerard; Weersma, Rinse K.; Parelsnoer Institute (PSI) and the Dutch Initiative on Crohn and Colitis (ICC)
(2017) BMJ open [E], volume 7, issue 11
(Article)
Abstract
PURPOSE: The Dutch IBD Biobank aims to facilitate the discovery of predictors for individual disease course and treatment response in patients with inflammatory bowel disease (IBD). In this paper, we aim to describe the establishment of the Dutch IBD Biobank, including the facilitators and barriers to establishment. Moreover, we aim
... read more
to provide a complete overview of the content of the Dutch IBD Biobank. PARTICIPANTS: Since 2007, every patient with IBD treated in one of the eight Dutch university medical centres is asked to participate in the Dutch IBD Biobank in which 225 standardised IBD-related data items and biomaterials, such as serum, DNA, biopsies and a stool sample, are collected. FINDINGS TO DATE: As of June 2014, the Dutch IBD Biobank had enrolled 3388 patients with IBD: 2118 Crohn's disease (62.5%), 1190 ulcerative colitis (35.1%), 74 IBD-unclassified (2.2%) and 6 IBD-indeterminate (0.2%). The inclusion of patients with IBD is ongoing. The quality of the biomaterials is good and serum, DNA and biopsies have been used in newly published studies. FUTURE PLANS: The genotyping (750 000 genetic variants) of all participants of the Dutch IBD Biobank is currently ongoing, enabling more genetic research. In addition, all participants will start reporting disease activity and outcome measures using an online platform and mobile app.
show less
Download/Full Text
Keywords: biobank, Crohn's disease, gastroenterology, inflammatory bowel disease, ulcerative colitis, General Medicine, Journal Article
ISSN: 2044-6055
Publisher: BMJ Publishing Group
Note: Funding Information: Competing interests FI reports personal fees for speaking from AbbVie. AAvB reports personal fees for consultation or speaking from AbbVie, Ferring, MSD, Takeda, Tramedico and VIFOR, he is member of the Committee on Drugs of the Dutch Society for Gastroenterology (NVMDL). RKW reports unrestricted research grants from Ferring and Tramedico, and personal fees during the conduct of the study from Abbott but outside the submitted work. AEvdMdJ reports unrestricted research grants from Takeda and Abbott, and personal fees during the conduct of the study from Abbott, Takeda and Tramedico outside the submitted work. NKHdB reports unrestricted research grant from FALK outside the submitted work, personal fees for consultation or speaking from AbbVie and Teva Pharma, and he is a member of the Advisory Board of MSD. Funding Information: Funding This nationwide PSI project is funded by the Netherlands Federation of University Medical Centres and it received initial funding from the Dutch government (from 2007 to 2011). PSI currently facilitates the uniform nationwide collection of information and biomaterials for 13 other diseases. This work is supported by the Netherlands Organisation for Scientific Research (NWO) (016.136.308 to RKW and 92.003.577 to MCV) and the Dutch Digestive Foundation (CDG 14-04 to EAMF). Publisher Copyright: © 2017 Article author(s) (or their employer(s) unless otherwise stated in the text of the article). All rights reserved.
(Peer reviewed)
